Rx Name [EMTRICITABINE|TENOFOVIR, 08180892]
|
|
EMTRICITABINE | TENOFOVIR 200MG | 300MG TAB (MAT/AHI)
|
|
|
|
|
|
08180892
|
|
|
ANTIRETROVIRALS MISCELLANEOUS
|
|
|
Indicated in combination ,with other antiretroviral agents (ARTs) for treatment of HIV-1 infection in adults.
HIV-1 Pre-exposure Prophylaxis Indicated for at-risk patients to reduce risk of HIV-1 infection from sex, excluding those at risk from recepti |
|
|
Lactic acidosis and severe hepatomegaly with steatosis. Emtricitabine/tenofovir should not be used as part of a triple nucleoside regimen. Emtricitabine/ tenofovir should not be coadministered with its individual components (i.e, emtricitabine or tenofovir) or with drugs containing lamivudine
|
|
|
One tablet once daily with or without food; not recommended for pediatric patients younger than 18 years
|
|
|
Concomitant use of emtricitabine/tenofovir DF (FTC/TDF) with certain drugs may result in known or potentially clinically important drug interactions, some of which may increase plasma concentrations of concomitant drugs leading to clinically important adverse reactions
|
|
|
|
|
|
The Centers for Disease Control and Prevention (CDC) and other experts recommend that HIV-infected women not breast-feed infants, regardless of antiretroviral therapy due to the risk of transmitting the virus through breastfeeding.
|
|
|
|